Q3-osavuosiraportti
UUTTA
5 päivää sitten‧36 min
Tarjoustasot
Oslo Børs
Määrä
Osto
1 800
Myynti
Määrä
941
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 200 | - | - | ||
| 659 | - | - | ||
| 1 674 | - | - | ||
| 856 | - | - | ||
| 144 | - | - |
Ylin
4,82VWAP
Alin
4,8VaihtoMäärä
0 5 533
VWAP
Ylin
4,82Alin
4,8VaihtoMäärä
0 5 533
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 12.11. | |
| 2025 Ylimääräinen yhtiökokous | 12.11. | |
| 2025 Q2-osavuosiraportti | 20.8. | |
| 2025 Q1-osavuosiraportti | 15.5. | |
| 2024 Yhtiökokous | 25.4. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·23 t sitten · MuokattuRisk of owning Life now is, among other things, if the answer from Noma is further delayed beyond the small window one has from approx. December 8 until the emission is set on January 2. Very unfortunate that the dates are so close to each other! If a positive answer comes in December, the price will go up somewhat, but the rise will be dampened as many will use the spike’n to sell in order to rather buy at a lower price which they know will come after January 2. Who would actually buy in on the spike’n when one knows there will be an emi with a large discount and a guaranteed lower price for everyone? This will put a big damper on a possible price increase. Best case scenario is a short-term rise (after positive news in Dec) to e.g. kr 7 and then there is really 1 strategy that applies, and that is to sell. (Alternative 1) 1. If you own today, e.g., 10k shares with an average of kr 10, then you sell at kr 7 and buy 20k shares at kr 3.5 after the emission. 20k shares then cost you 70k + the loss of kr 30k = costs you a total of 100k and gives you an average of 3.5. (20k shares, GAV 3.5, cost kr 100k)👍 2. If you, however, keep the position and add 10k shares at e.g. emi price of kr 3, then that will give you 20k shares with an average of 6.5 and cost you 130k. (20k shares, GAV 6.5, cost kr 130k). 👎 Worst case scenario If no news comes in December/message about further delay/rejection. One alternative - If you believe this will be the outcome, then sell all shares you have before the emission. Potentially buy back after the emission at a very low price. (Due to the above, much indicates that large parts of the emission will go to the guarantors)
·1 t sittenHere is the probability model based on today's known regulatory status for Lifecare. You get a simple, transparent scenario analysis, where each scenario has a probability and an explanation. The table above shows: 55 % probability of approval by December This is closest to NOMA's stated timeline, and the documentation is validated and complete. 30 % probability of minor delay (January) This is often due to external expert assessment or brief clarifications. 12 % probability of major postponement Typically if NOMA requests additional documentation, e.g., technical clarifications. 3 % probability of rejection This is considered low given current information.·46 min sittenN0obwars I asked Cgpt to search all available data and give an assessment. I also asked it to consider the fact that the share issue is added after expected approval and is not carried out at today's level. It agreed with me that this indicates that Lifecare expects approval in December and a price increase before the share issue. Everyone must make their own choices, but I am buying more at today's price. I don't think we will go down and expect an increase leading up to approval in December.
·3 päivää sittenI am surprised that the share price is holding up so well considering that the company will be diluted by 50% from today's value and at a 35% discount. I'll never make sense of the stock market.·2 päivää sittenWhy surprised? The issue price is not set until January and approval is expected in December. That should tell you something 😉 The share price can easily double upon approval.Poistettu·1 päivä sittenPoistettu·1 päivä sittenHow long does it take from approval to market? I think I agree with Fjasedal1 for the first time, it takes time.
·12.11.Quite a reaction. Nothing new that should make the stock go down. Of course, they need money until the product is out, but they are well on their way and will quite soon receive an answer on the approval which most likely will pave the way for CE approval in the future.·13.11.You must consider costs, revenues, and contracts in a completely different way when you talk about a company that is still in the development phase with its product. And there you have nothing but good news that tests have been passed, that clinical trials yield good results etc. which strengthens the hope that it will succeed and which drives the price...
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
UUTTA
5 päivää sitten‧36 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·23 t sitten · MuokattuRisk of owning Life now is, among other things, if the answer from Noma is further delayed beyond the small window one has from approx. December 8 until the emission is set on January 2. Very unfortunate that the dates are so close to each other! If a positive answer comes in December, the price will go up somewhat, but the rise will be dampened as many will use the spike’n to sell in order to rather buy at a lower price which they know will come after January 2. Who would actually buy in on the spike’n when one knows there will be an emi with a large discount and a guaranteed lower price for everyone? This will put a big damper on a possible price increase. Best case scenario is a short-term rise (after positive news in Dec) to e.g. kr 7 and then there is really 1 strategy that applies, and that is to sell. (Alternative 1) 1. If you own today, e.g., 10k shares with an average of kr 10, then you sell at kr 7 and buy 20k shares at kr 3.5 after the emission. 20k shares then cost you 70k + the loss of kr 30k = costs you a total of 100k and gives you an average of 3.5. (20k shares, GAV 3.5, cost kr 100k)👍 2. If you, however, keep the position and add 10k shares at e.g. emi price of kr 3, then that will give you 20k shares with an average of 6.5 and cost you 130k. (20k shares, GAV 6.5, cost kr 130k). 👎 Worst case scenario If no news comes in December/message about further delay/rejection. One alternative - If you believe this will be the outcome, then sell all shares you have before the emission. Potentially buy back after the emission at a very low price. (Due to the above, much indicates that large parts of the emission will go to the guarantors)·1 t sittenHere is the probability model based on today's known regulatory status for Lifecare. You get a simple, transparent scenario analysis, where each scenario has a probability and an explanation. The table above shows: 55 % probability of approval by December This is closest to NOMA's stated timeline, and the documentation is validated and complete. 30 % probability of minor delay (January) This is often due to external expert assessment or brief clarifications. 12 % probability of major postponement Typically if NOMA requests additional documentation, e.g., technical clarifications. 3 % probability of rejection This is considered low given current information.·46 min sittenN0obwars I asked Cgpt to search all available data and give an assessment. I also asked it to consider the fact that the share issue is added after expected approval and is not carried out at today's level. It agreed with me that this indicates that Lifecare expects approval in December and a price increase before the share issue. Everyone must make their own choices, but I am buying more at today's price. I don't think we will go down and expect an increase leading up to approval in December.
- ·3 päivää sittenI am surprised that the share price is holding up so well considering that the company will be diluted by 50% from today's value and at a 35% discount. I'll never make sense of the stock market.·2 päivää sittenWhy surprised? The issue price is not set until January and approval is expected in December. That should tell you something 😉 The share price can easily double upon approval.Poistettu·1 päivä sittenPoistettu·1 päivä sittenHow long does it take from approval to market? I think I agree with Fjasedal1 for the first time, it takes time.
- ·12.11.Quite a reaction. Nothing new that should make the stock go down. Of course, they need money until the product is out, but they are well on their way and will quite soon receive an answer on the approval which most likely will pave the way for CE approval in the future.·13.11.You must consider costs, revenues, and contracts in a completely different way when you talk about a company that is still in the development phase with its product. And there you have nothing but good news that tests have been passed, that clinical trials yield good results etc. which strengthens the hope that it will succeed and which drives the price...
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
1 800
Myynti
Määrä
941
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 200 | - | - | ||
| 659 | - | - | ||
| 1 674 | - | - | ||
| 856 | - | - | ||
| 144 | - | - |
Ylin
4,82VWAP
Alin
4,8VaihtoMäärä
0 5 533
VWAP
Ylin
4,82Alin
4,8VaihtoMäärä
0 5 533
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 12.11. | |
| 2025 Ylimääräinen yhtiökokous | 12.11. | |
| 2025 Q2-osavuosiraportti | 20.8. | |
| 2025 Q1-osavuosiraportti | 15.5. | |
| 2024 Yhtiökokous | 25.4. |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
UUTTA
5 päivää sitten‧36 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 12.11. | |
| 2025 Ylimääräinen yhtiökokous | 12.11. | |
| 2025 Q2-osavuosiraportti | 20.8. | |
| 2025 Q1-osavuosiraportti | 15.5. | |
| 2024 Yhtiökokous | 25.4. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·23 t sitten · MuokattuRisk of owning Life now is, among other things, if the answer from Noma is further delayed beyond the small window one has from approx. December 8 until the emission is set on January 2. Very unfortunate that the dates are so close to each other! If a positive answer comes in December, the price will go up somewhat, but the rise will be dampened as many will use the spike’n to sell in order to rather buy at a lower price which they know will come after January 2. Who would actually buy in on the spike’n when one knows there will be an emi with a large discount and a guaranteed lower price for everyone? This will put a big damper on a possible price increase. Best case scenario is a short-term rise (after positive news in Dec) to e.g. kr 7 and then there is really 1 strategy that applies, and that is to sell. (Alternative 1) 1. If you own today, e.g., 10k shares with an average of kr 10, then you sell at kr 7 and buy 20k shares at kr 3.5 after the emission. 20k shares then cost you 70k + the loss of kr 30k = costs you a total of 100k and gives you an average of 3.5. (20k shares, GAV 3.5, cost kr 100k)👍 2. If you, however, keep the position and add 10k shares at e.g. emi price of kr 3, then that will give you 20k shares with an average of 6.5 and cost you 130k. (20k shares, GAV 6.5, cost kr 130k). 👎 Worst case scenario If no news comes in December/message about further delay/rejection. One alternative - If you believe this will be the outcome, then sell all shares you have before the emission. Potentially buy back after the emission at a very low price. (Due to the above, much indicates that large parts of the emission will go to the guarantors)·1 t sittenHere is the probability model based on today's known regulatory status for Lifecare. You get a simple, transparent scenario analysis, where each scenario has a probability and an explanation. The table above shows: 55 % probability of approval by December This is closest to NOMA's stated timeline, and the documentation is validated and complete. 30 % probability of minor delay (January) This is often due to external expert assessment or brief clarifications. 12 % probability of major postponement Typically if NOMA requests additional documentation, e.g., technical clarifications. 3 % probability of rejection This is considered low given current information.·46 min sittenN0obwars I asked Cgpt to search all available data and give an assessment. I also asked it to consider the fact that the share issue is added after expected approval and is not carried out at today's level. It agreed with me that this indicates that Lifecare expects approval in December and a price increase before the share issue. Everyone must make their own choices, but I am buying more at today's price. I don't think we will go down and expect an increase leading up to approval in December.
- ·3 päivää sittenI am surprised that the share price is holding up so well considering that the company will be diluted by 50% from today's value and at a 35% discount. I'll never make sense of the stock market.·2 päivää sittenWhy surprised? The issue price is not set until January and approval is expected in December. That should tell you something 😉 The share price can easily double upon approval.Poistettu·1 päivä sittenPoistettu·1 päivä sittenHow long does it take from approval to market? I think I agree with Fjasedal1 for the first time, it takes time.
- ·12.11.Quite a reaction. Nothing new that should make the stock go down. Of course, they need money until the product is out, but they are well on their way and will quite soon receive an answer on the approval which most likely will pave the way for CE approval in the future.·13.11.You must consider costs, revenues, and contracts in a completely different way when you talk about a company that is still in the development phase with its product. And there you have nothing but good news that tests have been passed, that clinical trials yield good results etc. which strengthens the hope that it will succeed and which drives the price...
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
1 800
Myynti
Määrä
941
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 200 | - | - | ||
| 659 | - | - | ||
| 1 674 | - | - | ||
| 856 | - | - | ||
| 144 | - | - |
Ylin
4,82VWAP
Alin
4,8VaihtoMäärä
0 5 533
VWAP
Ylin
4,82Alin
4,8VaihtoMäärä
0 5 533
Välittäjätilasto
Dataa ei löytynyt